





















73. Taylor A, Vendramin C, Singh D, et al. von Willebrand factor/ADAMTS13 ratio at presentation of acute ischemic brain injury is predictive of outcome. *Blood Adv* 2020;4:398-407.
74. Denorme F, Kraft P, Pareyn I, et al. Reduced ADAMTS13 levels in patients with acute and chronic cerebrovascular disease. *PLoS One* 2017;12:e0179258.
75. Uemura M, Fujimura Y, Matsumoto M, et al. Comprehensive analysis of ADAMTS13 in patients with liver cirrhosis. *Thromb Haemost* 2008;99:1019-29.
76. Kobayashi S, Yokoyama Y, Matsushita T, et al. Increased von Willebrand Factor to ADAMTS13 ratio as a predictor of thrombotic complications following a major hepatectomy. *Arch Surg* 2012;147:909-17.
77. Lancellotti S, Basso M, Veca V, et al. Presence of portal vein thrombosis in liver cirrhosis is strongly associated with low levels of ADAMTS-13: a pilot study. *Intern Emerg Med* 2016;11:959-67.
78. Matsukawa M, Kaikita K, Soejima K, et al. Serial changes in von Willebrand factor-cleaving protease (ADAMTS13) and prognosis after acute myocardial infarction. *Am J Cardiol* 2007;100:758-63.
79. Joly BS, Darmon M, Dekimpe C, et al. Imbalance of von Willebrand factor and ADAMTS13 axis is rather a biomarker of strong inflammation and endothelial damage than a cause of thrombotic process in critically ill COVID-19 patients. *J Thromb Haemost* 2021;19:2193-8.
80. Bazzan M, Montaruli B, Sciascia S, et al. Low ADAMTS 13 plasma levels are predictors of mortality in COVID-19 patients. *Intern Emerg Med* 2020;15:861-3.
81. De Cristofaro R, Liuzzo G, Sacco M, et al. Marked von Willebrand factor and factor VIII elevations in severe acute respiratory syndrome coronavirus-2-positive, but not severe acute respiratory syndrome coronavirus-2-negative, pneumonia: a case-control study. *Blood Coagul Fibrinolysis* 2021;32:285-9.
82. Bowen DJ. An influence of ABO blood group on the rate of proteolysis of von Willebrand factor by ADAMTS13. *J Thromb Haemost* 2003;1:33-40.
83. Lynch CJ, Cawte AD, Millar CM, et al. A common mechanism by which type 2A von Willebrand disease mutations enhance ADAMTS13 proteolysis revealed with a von Willebrand factor A2 domain FRET construct. *PLoS One* 2017;12:e0188405.
84. Meyer AL, Malehsa D, Bara C, et al. Acquired von Willebrand syndrome in patients with an axial flow left ventricular assist device. *Circ Heart Fail* 2010;3:675-81.
85. Lee M, Rodansky ES, Smith JK, Rodgers GM. ADAMTS13 promotes angiogenesis and modulates VEGF-induced angiogenesis. *Microvasc Res* 2012;84:109-15.
86. Qin F, Impeduglia T, Schaffer P, Dardik H. Overexpression of von Willebrand factor is an independent risk factor for pathogenesis of intimal hyperplasia: preliminary studies. *J Vasc Surg* 2003;37:433-9.
87. Ishihara J, Ishihara A, Starke RD, et al. The heparin binding domain of von Willebrand factor binds to growth factors and promotes angiogenesis in wound healing. *Blood* 2019;133:2559-69.
88. Starke RD, Ferraro J, Paschalaki KE, et al. Endothelial von Willebrand factor regulates angiogenesis. *Blood* 2011;117:1071-80.
89. Lee M, Keener J, Xiao J, et al. ADAMTS13 and its variants promote angiogenesis via upregulation of VEGF and VEGFR2. *Cell Mol Life Sci* 2015;72:349-56.
90. Eugenholtz GC, Adelmeijer J, Meijers JC, et al. An imbalance between von Willebrand factor and ADAMTS13 in acute liver failure: implications for hemostasis and clinical outcome. *Hepatology* 2013;58:752-61.
91. Seth R, McKinnon TAJ, Zhang XF. Contribution of the von Willebrand factor/ADAMTS13 imbalance to COVID-19 coagulopathy. *Am J Physiol Heart Circ Physiol* 2022;322:H87-H93.

Non-commercial use only